Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Resiquimod

Drug Profile

Resiquimod

Alternative Names: R 848; S 28463; VML 600

Latest Information Update: 21 Dec 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 3M Pharmaceuticals
  • Developer Spirig Pharma
  • Class Adjuvants; Antineoplastics; Antivirals; Imidazoles; Quinolones; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunostimulants; Interferon alpha stimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Actinic keratosis; Basal cell cancer; Hepatitis C; Herpes simplex virus infections; Immunological disorders

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 24 Oct 2013 Spirig Pharma discontinues a phase II trial in Basal cell carcinoma in Germany (NCT01808950)
  • 04 Sep 2013 Spirig Pharma discontinues a phase II trial in Actinic keratosis in Germany and Switzerland (NCT01806961)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top